Uncategorized

This 15-day drop has now seen the stock fall below all of its key moving averages.

Before making any moves, let’s get one thing straight—this correction was different from some of the big corrections from the pre-pandemic era. It wasn’t triggered by a specific negative event but by concerns over slowing earnings growth.

IREDA Share Price | The company’s borrowing limit for the financial year 2025 has been increased from ₹24,200 crore to ₹29,200 crore.

None among the four analysts who have coverage on IKS Health have a “buy” rating on the stock. Instead, all four of them have a “hold” rating.

Brokerage firm UBS said that market’s negative perceptions of HAL is misplaced and does not reflect the company’s long-term growth potential.

IRCON International is covered by three analysts and none of them have a “buy” recommendation on the stock.

Last month, brokerages Bernstein and Citi raised their target prices on Devyani International. While Bernstein has an “Outperform” rating on the stock with twelve-month target price of ₹220, Citi suggested a “Buy” with a target price of ₹210.

According to DAM Capital, an extended and more intense summer, along with a 20% year-on-year capacity expansion, is expected to drive strong near-term demand acceleration.

The new platform, which will underpin many of its future electric vehicles, could provide another boost for BYD, which has come from behind to rival Tesla Inc. as the world’s top EV seller.

On Tuesday, market tech analysts Shilpa Rout, Mitessh Thakkar and F&O analyst Chandan Taparia recommended these stocks for the short term.